BioCardia Announces FDA Acceptance of De Novo Pre-Submission Package for Helix(TM) Catheter Marketing Clearance FDA Substantive Review and Meeting Expected this Quarter

Stock Information for BioCardia Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About BioCardia Inc.

BioCardia Presents CardiAMP HF II Trial Design at Heart Failure Society of America Annual Scientific Meeting
BioCardia Files Revised De Novo Pre-Submission for FDA Approval of Helix(TM) Catheter
BioCardia Confirms Timing and Provides Update on FDA Helix Pre-Submission and PMDA CardiAMP HF Shonin Submission
BioCardia to Present CardiAMP Regulatory and Corporate Progress at H.C. Wainwright 28th Annual Global Investment Conference
BioCardia Announces FDA Confirms Helix Transendocardial Delivery Catheter Meeting Minutes Supporting Follow-On De Novo Pre-Submission for Approval
BioCardia Reports Second Quarter 2026 Business Highlights and Financial Results
BioCardia to Host Q2 2026 Financial Results and Corporate Update Conference Call on August 12, 2026
BioCardia Letter to Stockholders on 2026 Priorities and Strategic Opportunities

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.